| CAS NO: | 1218-35-5 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| 25g | 电议 |
| Molecular Weight (MW) | 280.84 |
|---|---|
| Formula | C16H24N2.HCl |
| CAS No. | 1218-35-5 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 27 mg/mL (96.1 mM) |
| Water: 56 mg/mL (199.4 mM) | |
| Ethanol: 56 mg/mL (199.4 mM) | |
| Other info | Chemical Name: 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole hydrochloride InChi Key: YGWFCQYETHJKNX-UHFFFAOYSA-N InChi Code: InChI=1S/C16H24N2.ClH/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15;/h8-9H,6-7,10H2,1-5H3,(H,17,18);1H SMILES Code: CC1=C(CC2=NCCN2)C(C)=CC(C(C)(C)C)=C1.[H]Cl |
| Synonyms | Trade name: Otrivine; Amidrin; Balkis; Chlorohist-LA; Decongest; espa-rhin; Gelonasal. |
| In Vitro | In vitro activity: Xylometazoline is an α-adrenoceptor agonist commonly used as nasal decongestant, exhibits highest potency at α2B-adrenoceptor subtype with EC50 of 99 μM. Xylometazoline binds at adrenoceptor subtypeα1A, α1B, α1D, α2A, α2B, α2C with IC50 of 0.08, 0.56, 0.45, 0.98, 1.8, 0.22μM, repectively. |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. |
m.cnreagent.com